Cytek Biosciences (CTKB) Net Income towards Common Stockholders (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$18.9 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 65.46% year-over-year to -$18.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$74.0 million (down 557.69% YoY) and the FY2025 annual result came in at -$66.5 million, down 1005.3% from the prior year.
• Net Income towards Common Stockholders advanced to -$18.9 million in Q1 2026, from -$44.1 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $9.6 million in Q4 2024 to a low of -$44.1 million in Q4 2025.
• A 5-year average of -$5.9 million and a median of -$5.5 million in 2025 frame the typical range for Net Income towards Common Stockholders.
• The widest YoY moves for Net Income towards Common Stockholders: up 381.5% in 2022, down 2081.37% in 2022.
• Tracing CTKB's Net Income towards Common Stockholders over 5 years: stood at $3.5 million in 2022, then surged by 55.94% to $5.5 million in 2023, then jumped by 75.23% to $9.6 million in 2024, then slumped by 557.08% to -$44.1 million in 2025, then surged by 57.2% to -$18.9 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$18.9 million (Q1 2026), -$44.1 million (Q4 2025), and -$5.5 million (Q3 2025), per Business Quant data.